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Management of patients presenting to the Emergency Department with chest pain is continuously evolving. In the setting of
acute coronary syndrome, the availability of high-sensitivity cardiac troponin assays (hs-cTn) has allowed for the development
of algorithms aimed at rapidly assessing the risk of an ongoing myocardial infarction. However, concerns were raised about the
massive application of such a simplified approach to heterogeneous real-world populations. As a result, there is a potential risk of
underdiagnosis in several clusters of patients, including women, for whom a lower threshold for hs-cTn was suggested to be more
appropriate. Implementation in clinical practice of sex-tailored cut-off values for hs-cTn represents a hot topic due to the need to
reduce inequality and improve diagnostic performance in females. The aim of this review is to summarize current evidence on
sex-specific cut-off values of hs-cTn and their application and usefulness in clinical practice. We also offer an extensive overview of
thresholds reported in literature and of the mechanisms underlying such differences among sexes, suggesting possible explanations
about debated issues.
1. Background
Chest pain is one of the most common symptoms and
reasons for admission in patients who present to the Emer-
gency Department (ED) [1, 2], setting a major challenge
for emergency physicians due to the large number of con-
ditions included in the differential diagnosis [3, 4]. These
include cardiovascular diseases (e.g., stable angina, acute
coronary syndrome (ACS), aortic dissection, and pulmonary
embolism) as well as a broad spectrum of non-cardiovascular
causes, such as pneumonia, pleuritis, gastrointestinal disease,
and psychogenic causes [5, 6].
In this setting, the first and most important diagnosis
to exclude is ACS, due to its high rates of morbidity and
mortality [7, 8] and to the need for a prompt therapeutic inter-
vention in case of a confirmedmyocardial infarction (MI) [9,
10]. Cardiac troponin (cTn), a protein involved in cardiomy-
ocyte contraction, is a reliable and widely used biomarker of
cardiac injury. Its measurement plays an essential role in the
diagnostics of ACS [11], to the point of its being included in
the universal definition of MI [12]. The availability of a both
sensitive and specific marker of myocardial injury, especially
with the introduction of the newest high-sensitivity assays
(hs-cTn), has revolutionized the workup of ACS in the ED.
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With this comes the newfound ability to rule out suspected
ongoing ischemic heart disease in patients presenting with
chest pain and no obvious electrocardiographic signs of MI
[13].
To date, a concentration of hs-cTn above the assay-
specific upper reference limit (derived from a reference
population) is used as a cut-off point for the diagnosis of
MI [12]. However, the application of one standard threshold
value may not be appropriate for all patients. Sex is one of
the several variables that could influence its concentration
and interpretation, potentially leading to underdiagnosis
and inequality in the treatment of acute MI in women.
Coronary artery disease (CAD) and MI are primary causes
of mortality in the female population [14]. This is partly
due to the frequent atypical clinical presentation in this
group, which complicates recognition of symptoms, and
can delay following interventions. Moreover, a recent study
has shown that women with MI suffer from higher excess
mortality compared to men, a difference which is reduced
after adjusting for the use of guideline-indicated care [15].
The aim of this review is to summarize the available evi-
dence on the influence of sex on the diagnostic performance
of hs-cTn and to present novel implications and applications
of sex-specific cut-offs in the management of ACS. For
this purpose, we searched for relevant articles on PubMed,
combining the terms “troponin”, “hs-cTn”, “gender”, “sex”,
“women”, “females”, “men” and “males”.
2. Cardiac Troponin: Silver Bullet in the
Diagnostics of ACS and MI
The troponin complex is a well-known component of the
skeletal and cardiac muscles and plays a key role in myocyte
contraction. The complex is composed of three subunits
(troponin C, troponin I, and troponin T), each with a
peculiar function in the genesis of contraction [16]. Unlike
the C subunit, troponins I and T are expressed in the heart
in cardiac-specific isoforms (cTnI and cTnT, respectively),
allowing them to be recognized as belonging to cardiomy-
ocytes. Following ischemic and non-ischemic myocardial
injury, plasmatic levels of both cTnI and cTnT begin to
increase and become detectable [11], with kinetics that mostly
depend on the type of damage and, in the case of ischemic
injury, on the duration of the ischemia and the timing of
reperfusion [17]. Usually, troponin levels begin to increase
2 to 4 hours after an ischemic event and remain high for as
long as 14 days [18]. Because of these characteristics, cTnI
and cTnThave established themselves as themain biomarkers
used in the diagnostics of ACS and MI [11, 12]. The advent
of hs-cTn has led to an improved ability in detecting slight
increases or variations in troponin blood levels, thus resulting
in a better chance of rapidly identifying a higher number of
MI [19]. Simultaneously, hs-cTn have also increased the safety
and reliability of ruling out those patients with stable, low
concentrations of hs-cTn and an unlikely ongoingMI [20, 21].
One of the most important open issues regarding the use
of hs-cTn is the biological variability in baseline troponin
levels, and how this could impact their role in the diagnostics
of ACS [19]: 99th percentile levels of hs-cTn are broadly
used as the cut-off to rule in or rule out possible MI. These
are obtained by studying reference populations composed of
supposedly healthy people, but questions were raised about
the suitability of using a single cut-off in a heterogeneous
real-world population in which patients differ in age, sex, and
comorbidities [19, 22]. Some authors argue that serial mea-
surements of hs-cTn could lead to an enhanced prognostic
value of this marker by detecting relevant changes in its levels
[23–25], thus highlighting the importance of weighting intra-
patient variability for the interpretation of hs-cTn values.
Indeed, a growing number of studies suggest that the use of a
single threshold for hs-cTn irrespective of age, sex, and other
parameters may not be ideal [22, 26–28].
Furthermore, several concerns were raised about the
definition of hs-cTn, with an ensuing struggle to state
unequivocal criteria to identify the necessary standard to be
met by an assay in order to be labelled as “high-sensitivity”
[29–31]. Consensus of experts proposed a definition that
identifies cTn assays as “high-sensitivity” if two criteria are
met: (a) total imprecision (i.e., coefficient of variation) ≤10%
at the value of the 99th percentile; (b) ability to measure levels
of cTn between limit of detection and 99th percentile in at
least 50% of healthy subjects [29, 32, 33].
3. Sex and Gender: One Key Factor to Consider
When Dealing with Troponins
In the context of cardiovascular disease, several differences
betweenmen andwomenhave been described [34]. As for the
diagnosis of cardiovascular disease, concentrations of several
biomarkers were found to be influenced by sex [35–39],
including hs-cTn [40–43], with men reportedly presenting
higher concentrations thanwomen. Accordingly, the need for
sex-specific reference values has been pointed out by several
authors [44–47], while other studies indicate that adopting
sex-specific reference intervals for other biomarkers, such as
total creatine kinase (CK) activity and MB fraction of CK
[48], could also have potential benefits. The same applies
to natriuretic peptides [36, 49–53], growth hormone [54],
galectin-3 [55, 56], soluble ST2 [57, 58], and proneurotensin
[59, 60], supporting the idea that sex differences should be
taken into account when approaching laboratory tests.
The first cTn assays, however, required the use of a
single, universal cut-off value [61]. The development of hs-
cTn assays, in addition to increasing analytical sensitivity, has
shown that men present significantly higher concentrations
than women for both hs-cTnT and hs-cTnI, highlighting that
the upper reference limit for the diagnosis ofMI could be two-
fold inmen compared towomen, regardless of the assay being
used [29, 44, 61–63].
While still far from being comprehensively understood,
several mechanisms may contribute to the aforementioned
discrepancy between men and women (Figure 1). Based on
the fact that troponin is a measure for the amount of dam-
aged myocardium, some evidence suggests that differences
in plasmatic levels of hs-cTn could be attributed to sex-
specific variations in body composition [64], cardiac mass
[65, 66], and rate of cardiomyocyte apoptosis due to cardiac
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Figure 1: Mechanisms contributing to the discrepancy in hs-cTn levels between men and women.
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Figure 2: Chart showing different 99th percentile values for hs-cTnT (panel a) and hs-cTnI (panel b) assays, derived from selected population
studies as reported in Tables 1 and 2. Bold lines represent non-sex-specific, standard cut-offs for hs-cTnT and hs-cTnI (14 ng/L and 26 ng/L,
respectively).
remodeling [67]. Some insight was provided by authors
who outlined potential mechanisms of troponin shedding
in the absence of overt membrane injury: variations in the
regulation of these events may partially explain the observed
variability across healthy subjects [68]. Myocardial response
to ischemia and reperfusion is assumed to be unequal in men
and women, as well as the pathophysiological mechanism
of cardiac ischemia, the grade of coronary atherosclerosis,
and the presence of collateral blood flow [69–71]. Sexual
hormonesmay also play a role in the differential expression of
hs-cTn levels. Estrogens are thought to exert a protective role
on the myocardium: their antioxidant properties and their
ability to scavenge reactive oxygen species may contribute to
limit cardiomyocyte injury [43, 72–74].
4. Sex-Related Cut-Offs: State of the Art
The 99th percentile reference limit (14 ng/L) for hs-cTnT assay
(RocheDiagnostics) was set by a study of over 600 apparently
healthy volunteers and blood donors [62] and subsequently
restated in a multicenter cohort study [75]. In both studies,
50% of the population was composed of females and women
showed significantly lower 99th percentile concentrations of
hs-cTnT compared to men (10.0 versus 14.5 ng/L and 8.9
versus 15.5 ng/L, respectively). Several other studies support
the existence of a discrepancy between 99th percentile values
of hs-cTnT inmen and women (Table 1 and Figure 2-panel a).
Another large study, based on threewide cohorts, reports sex-
related critical differences in reference values of hs-cTnT [44],
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and an Italian-based study of 1600 healthy subjects confirmed
the lower threshold for the 99th percentiles in females, with
the discrepancy consistent in each age-class [76]. This trend
is strongly supported by several other studies, although ref-
erence values differ substantially between populations, thus
highlighting the impact of the cohort’s characteristics [40,
61, 77–82]. Criteria used for the identification of “healthy”
individuals are among themost importantmatters of concern
when recruiting a reference population for the purpose of
identifying reference values. An elegant study sheds light
on how these factors could affect the process of setting a
standard reference limit: subsequent application of stricter
selection criteria resulted in a progressive reduction of 99th
percentile values in a cohort of supposedly healthy people
[83], thus addressing the need to implement laboratory
tests and clinical assessments in the process of identifying
a reference population. These findings are consistent with
those observed in other studies [40, 44] and highlight the
importance of taking patients’ variables into account when
dealing with troponins.
Unlike hs-cTnT, several hs-cTnI assays have been devel-
oped [84]. The 99th percentile reference values, limits of
detection and variance coefficients all vary between assays
[19]. Despite these major differences, and consistently with
data on hs-cTnT, several studies identified sex-related differ-
ences in reference limits of hs-cTnI (Table 2 and Figure 2-
panel b). 99th percentile reference values of hs-cTnI were
found to be systematically lower in females, regardless of the
assay used, ethnicity of the population, or criteria used to
identify healthy cohorts. Still, these factors heavily affect the
point estimates of the 99th percentile, which differ across the
studies [27, 61, 63, 78, 80, 85–90].
5. Application of Sex-Specific Cut-Offs in
Clinical Practice
While there is a considerable body of evidence to support
the role of sex in influencing reference levels of troponin, no
definitive data are available on how this discrepancy could
affect the diagnostic and prognostic value of hs-cTn in the
work-up of ACS. A synopsis of the studies assessing the
prognostic performance of sex-specific cut-offs is reported
in Table 3. Specifically, the impacts of three sex-specific cut-
offs for hs-cTnT, as reported by Saenger et al. [75], Gore
et al. [44], and Kimenai et al. [78], were evaluated in a
cohort of patients recruited in an ongoing trial (n=2734,
32% women), each presenting with suspected acute MI.
Women were significantly older than men (median age
[IQR]: 68 [55-77] versus 59 [48-71]) and showed lower
estimated glomerular filtration rate values, whilst higher
rates of CAD history and smoking were reported in men.
With the application of sex-specific cut-offs instead of the
universal one, reclassification from unstable angina (UA) to
non-ST elevation MI (NSTEMI) occurred in two women,
while only one man was downgraded to UA from NSTEMI.
Similar findings were reported with all three sex-based cut-
off values analyzed. Reclassification was not shown to impact
short-term or long-term prognosis in this cohort, thus not
providing evidence in favor of the application of sex-specific
thresholds in the diagnostics of ACS [91]. These findings
are supported by a subanalysis of the TRAPID-AMI (The
High Sensitivity Cardiac Troponin T Assay for Rapid Rule-
out of Acute Myocardial Infarction) study, which enrolled
over 1200 patients (37% women) with chest pain to assess
whether the application of Saenger’s sex-oriented cut-offs for
hs-cTnT would lead to a better reclassification of MI and
an improvement in prognosis. While the use of different
cut-offs resulted in an increase of acute MI rates in females
(from 16.6% to 22.6%) and a decrease in males, this did not
produce any benefit in terms of outcomes [92]. Furthermore,
a large retrospective study showed slightly higher rates of
diagnostic reclassification (8,4%) and an increase (+3.3%)
in MI prevalence in women when using sex-specific cut-
offs. Although this study confirmed no advantage in risk
prediction when using sex-specific reference values, the risk
inwomenwas increased at levels of 10-12 ng/L, which is below
the set standard point of 14 ng/L [93]. A recent observational
study, focused on the diagnostic performance of several sex-
specific hs-cTnT cut-offs for the rule-out of MI, showed an
improved specificity with the adoption of different threshold
levels [94]. These findings were also consistent with a recent
Chinese study in which sex-specific cut-offs were calculated
in an original reference population and then further stratified
according to age. This study reports an increased specificity
for sex-related hs-cTnT thresholds in the diagnostics of AMI,
as well as higher negative and positive predictive values [95].
However, the impact of age-stratification probably played
a decisive role in this study, still highlighting a possible
interplay between these two variables.
The recently published High-STEACS (The High Sen-
sitivity Cardiac Troponin T Assay for Rapid Rule-out of
Acute Myocardial Infarction) study reports some of the most
interesting findings to date on the topic of sex-specific cut-
offs for hs-cTn and on the potential magnitude of the impact
which their implementation could have in themanagement of
patients with suspected ACS. In this multicenter, randomized
control trial a high sensitivity (hs-cTnI) and a contemporary
(cTnI) assay were compared in the diagnosis of suspected
ACS. In the first phase of the study, clinical decisions
were made according to the cTnI values, while the hs-cTnI
concentration was masked. In the second phase, clinicians
were provided with the hs-cTnI levels, while cTnI values were
masked.The 99th percentiles for hs-cTnI were set to 34 ng/mL
and 16 ng/mL in men and women, respectively. Compared
with the contemporary assay, reclassification occurred in a
significant part (17%) of the myocardial injuries identified by
the hs-cTnI, with twofold frequency in women compared to
men. However, no significant differences were observed in
1-year outcomes among reclassified patients treated accord-
ing to cTnI versus hs-cTnI levels [96]. These findings are
consistent with a multicenter observational study by Cullen
et al., the first large investigation reporting the effects of
sex-specific cut-offs (34 ng/L for males and 16 ng/L for
females) on prediction of Major Adverse Cardiac Events
(MACE) in ED patients. This study suggests that the use
of sex-specific reference values for hs-cTnI improves the
6 Cardiovascular Therapeutics
Ta
bl
e
2:
St
ud
ie
sr
ep
or
tin
g
9
9
th
pe
rc
en
til
e
va
lu
es
fo
rh
s-
cT
nI
in
di
ffe
re
nt
re
fe
re
nc
e
po
pu
lat
io
ns
.†
=m
ed
ia
n
[IQ
R]
;
a =
on
ly
ra
ng
e
pr
ov
id
ed
;B
M
I:
bo
dy
m
as
si
nd
ex
;B
N
P:
br
ai
n
na
tr
iu
re
tic
pe
pt
id
e;
CI
:c
on
fid
en
ce
in
te
rv
al
;c
Tn
:c
ar
di
ac
tro
po
ni
n;
eG
FR
:e
st
im
at
ed
gl
om
er
ul
ar
fil
tr
at
io
n
ra
te
;H
bA
1c
:g
ly
ca
te
d
he
m
og
lo
bi
n;
U
S:
U
ni
te
d
St
at
es
.
St
ud
y
St
ud
y
ob
je
ct
iv
e
Ye
ar
Lo
ca
tio
n
St
ud
y
po
pu
la
tio
n
A
ge
,m
ea
n
±
SD
Po
pu
lat
io
n,
ac
co
rd
in
g
to
se
x
9
9
th
pe
rc
en
til
e(
ng
/L
)[
95
%
CI
]
C
om
m
en
ts
M
al
es
(%
)
Fe
m
al
es
(%
)
M
al
es
Fe
m
al
es
hs
-c
Tn
I(
Ab
bo
tt
D
ia
gn
os
tic
s)
Ap
pl
ee
ta
l.
[6
1]
To
sy
ste
m
at
ic
al
ly
as
se
ss
9
9
th
pe
rc
en
til
es
of
cT
n
co
nc
en
tr
at
io
ns
in
as
in
gl
ep
op
ul
at
io
n
fo
ra
la
rg
en
um
be
ro
fa
ss
ay
s
20
12
U
S
52
4
18
-6
4a
27
2
(5
2)
25
2
(4
8)
36
15
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
ly
on
he
al
th
qu
es
tio
nn
ai
re
in
te
rv
ie
w
s
Ko
er
bi
n
et
al
.
[6
3]
To
as
se
ss
an
al
yt
ic
al
ch
ar
ac
te
ris
tic
sa
nd
to
ap
pl
y
th
ea
ss
ay
to
ap
op
ul
at
io
n
of
ap
pa
re
nt
ly
ca
rd
io
va
sc
ul
ar
di
se
as
e-
fre
ep
eo
pl
e
20
12
Au
str
al
ia
49
7
20
-8
4a
23
1(
46
.5
)
26
6
(5
3.
5)
14
11
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
m
ed
ic
al
hi
sto
ry
an
d
bi
om
ar
ke
rs
Aw
et
al
.[
85
]
To
de
te
rm
in
e9
9
th
pe
rc
en
til
er
ef
er
en
ce
va
lu
es
in
al
ar
ge
A
sia
n
co
ho
rt
20
13
A
sia
11
20
50
.4
±
8.
2
59
7
(5
3.
3)
52
3
(4
6.
7)
32
.7
17.
9
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
:m
ed
ic
al
hi
sto
ry
Kr
in
tu
se
ta
l.
[2
7]
To
as
se
ss
9
9
th
pe
rc
en
til
ef
or
hs
-c
Tn
Ii
n
al
ar
ge
m
ul
tic
en
te
rE
ur
op
ea
n
co
ho
rt
20
15
Eu
ro
pe
17
69
49
[1
8-
60
]†
77
6
(4
3.
9)
99
3
(5
6.
1)
27
11
.4
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
bl
oo
d
do
no
rs
,h
ea
lth
qu
es
tio
nn
ai
re
sa
nd
no
ov
er
t
ca
rd
io
va
sc
ul
ar
di
se
as
e
O
m
la
nd
et
al
.
[8
6]
To
as
se
ss
se
x-
re
la
te
d
di
ffe
re
nc
es
in
hs
-c
Tn
I
di
str
ib
ut
io
n
ac
ro
ss
se
xe
s
20
15
N
or
w
ay
80
99
M
al
es
:5
0.
2
±
17.
1
36
70
(4
5.
3)
44
29
(5
4.
7)
34
.8
[2
6.
3-
49
.4
]
18
.7
[14
.8
-2
3.
1]
Re
fe
re
nc
ei
nt
er
va
ls
ar
er
ep
or
te
d
fo
rw
om
en
an
d
m
en
w
ith
ou
th
ist
or
y
of
m
aj
or
ca
rd
io
va
sc
ul
ar
di
se
as
eo
rr
isk
fa
ct
or
Fe
m
al
es
:4
9.7
±
16
.4
Ze
lle
re
ta
l.
[8
7]
To
as
se
ss
se
x-
sp
ec
ifi
c9
9
th
pe
rc
en
til
er
ef
er
en
ce
va
lu
es
in
al
ar
ge
G
er
m
an
-b
as
ed
co
ho
rt
20
15
G
er
m
an
y
41
38
50
[4
2
−
6
1
]†
20
98
(5
0.
7)
20
40
(4
9.3
)
33
.1
[2
8.
3-
45
.8
]
19
.9
[1
6.
1-2
3.
9]
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
di
ffe
re
nt
cr
ite
ria
w
ith
se
ve
ra
ls
ub
gr
ou
ps
re
po
rt
ed
(h
er
et
he
ov
er
al
l)
15
35
(w
ho
le
co
ho
rt
)
57
±
8
73
3
(4
7.6
)
80
7
(5
2.
4)
20
[14
-2
2]
11
[8
-1
3]
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
:m
ed
ic
al
hi
sto
ry
an
d
bi
om
ar
ke
rs
;p
op
ul
at
io
n
str
at
ifi
ed
by
ag
e
Ki
m
en
ai
et
al
.
[7
8]
To
as
se
ss
se
x-
sp
ec
ifi
ca
nd
ag
e-
sp
ec
ifi
c9
9
th
pe
rc
en
til
eu
pp
er
re
fe
re
nc
el
im
its
of
hs
-c
Tn
T
an
d
hs
-c
Tn
Ii
n
as
in
gl
er
ef
er
en
ce
co
ho
rt
20
16
N
et
he
rla
nd
s
28
3
40
-4
9
12
0
(4
2.
4)
16
3
(5
7.6
)
13
[5
-1
5]
12
[1
0-
14
]
94
4
50
-6
4
44
1(
46
.7
)
50
3
(5
3.
3)
22
[1
3-
23
]
9
[6
-1
4]
30
8
65
-7
5
16
8
(5
4.
5)
14
0
(4
5.
6)
20
[1
3-
25
]
13
[1
0-
13
]
M
ue
lle
re
ta
l.
[8
0]
To
as
se
ss
9
9
th
pe
rc
en
til
ei
n
ab
lo
od
do
no
rs
po
pu
la
tio
n
20
16
Au
str
ia
40
2
35
[2
5.
9-
45
.1]
†
25
9
(6
4.
4)
14
3
(3
5.
6)
39
.0
23
.5
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
:n
o
ov
er
t
ca
rd
io
va
sc
ul
ar
di
se
as
e,
eG
FR
>
90
m
l/m
in
Ji
et
al
.[
88
]
To
as
se
ss
9
9
th
pe
rc
en
til
ev
al
ue
si
n
aK
or
ea
n
co
ho
rt
20
16
So
ut
h
Ko
re
a
85
4
49
.8
±
10
.2
42
6
(4
9.9
)
42
8
(5
0.
1)
20
19
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
cli
ni
ca
l
hi
sto
ry
an
d
la
bo
ra
to
ry
te
sts
(e
G
FR
,H
bA
1c
,B
N
P)
Li
et
al
.[
89
]
To
as
se
ss
9
9
th
pe
rc
en
til
ef
or
hs
-c
Tn
Ii
n
a
Ch
in
es
e-
ba
se
d
po
pu
lat
io
n
20
17
Ch
in
a
14
85
36
±
13
73
1(
49
.2
)
75
4
(5
0.
8)
31
.1
22
.7
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
:c
lin
ic
al
hi
sto
ry
,B
M
I,
re
na
lf
un
ct
io
n
W
els
h
et
al
.[
10
8]
Ev
al
ua
tin
g
th
ei
nfl
ue
nc
eo
fs
ev
er
al
va
ria
bl
es
,
in
clu
di
ng
se
x,
on
th
e9
9
th
pe
rc
en
til
el
ev
els
of
hs
-c
Tn
T
an
d
hs
-c
Tn
I
20
18
Sc
ot
la
nd
19
50
1
35
-6
5a
81
26
(4
1.7
)
11
37
5
(5
8.
3)
Se
ve
ra
l
ac
co
rd
in
g
to
ag
e
Se
ve
ra
l
ac
co
rd
in
g
to
ag
e
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
ge
ne
ra
l
po
pu
la
tio
n;
he
al
th
qu
es
tio
nn
ai
re
;l
ab
te
sts
hs
-c
Tn
I(
Be
ck
m
an
C
ou
lte
r)
Ap
pl
ee
ta
l.
[6
1]
To
sy
ste
m
at
ic
al
ly
as
se
ss
9
9
th
pe
rc
en
til
es
of
cT
n
co
nc
en
tr
at
io
ns
in
as
in
gl
ep
op
ul
at
io
n
fo
ra
la
rg
en
um
be
ro
fa
ss
ay
s
20
12
U
S
52
4
18
-6
4a
27
2
(5
2)
25
2
(4
8)
52
23
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
ly
on
he
al
th
qu
es
tio
nn
ai
re
in
te
rv
ie
w
s
hs
-c
Tn
I(
Si
ng
ul
ex
)
Ap
pl
ee
ta
l.
[4
1]
To
de
te
rm
in
e9
9
th
pe
rc
en
til
er
ef
er
en
ce
va
lu
e
fo
rh
s-
cT
nI
as
sa
y
20
10
U
S
34
8
18
-7
6a
14
7
(4
2.
2)
20
1(
57
.8
)
16
.6
9.4
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
ly
on
he
al
th
qu
es
tio
nn
ai
re
in
te
rv
ie
w
s
Bo
ss
ar
d
et
al
.[
90
]T
o
as
se
ss
fa
ct
or
sr
el
at
ed
to
hs
-c
Tn
Il
ev
els
in
a
he
al
th
y
yo
un
g
po
pu
la
tio
n
w
ith
ou
to
ve
rt
ca
rd
io
va
sc
ul
ar
di
se
as
es
20
16
Li
ec
ht
en
ste
in
20
77
36
.7
[3
1.1
-4
0.
2]
†
97
5
(4
6.
9)
110
2
(5
3.
1)
15
.8
5.
1
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
:c
lin
ic
al
re
co
rd
sa
nd
ab
se
nc
eo
fc
om
or
bi
di
tie
s
hs
-c
Tn
I(
Si
em
en
s)
Ap
pl
ee
ta
l.
[6
1]
To
sy
ste
m
at
ic
al
ly
as
se
ss
9
9
th
pe
rc
en
til
es
of
cT
n
tro
po
ni
n
co
nc
en
tr
at
io
ns
in
as
in
gl
ep
op
ul
at
io
n
fo
ra
la
rg
en
um
be
ro
fa
ss
ay
s
20
12
U
S
52
4
18
-6
4a
27
2
(5
2)
25
2
(4
8)
81
42
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
ly
on
he
al
th
qu
es
tio
nn
ai
re
in
te
rv
ie
w
s
M
cK
ie
et
al
.[
42
]
To
de
fin
eh
s-
cT
nI
re
fe
re
nc
ev
al
ue
sa
nd
de
te
rm
in
an
ts
in
th
eg
en
er
al
co
m
m
un
ity
,i
n
a
he
al
th
y
re
fe
re
nc
ec
oh
or
t,
an
d
in
su
bs
et
sw
ith
di
se
as
es
20
13
U
S
56
5
54
[5
0-
61
]†
26
0
(4
5)
30
5
(5
4)
55
[3
2-
12
4]
33
[2
2-
15
5]
Re
fe
re
nc
ep
op
ul
at
io
n
se
le
ct
io
n
ba
se
d
on
m
ed
ic
al
hi
sto
ry
,b
io
m
ar
ke
rs
an
d
ca
rd
ia
ci
m
ag
in
g
Cardiovascular Therapeutics 7
Table 3: Studies reporting performance and prognostic impact of sex-specific cut-offs in different populations. MACE: major adverse
cardiovascular events; MI: myocardial infarction.
Study Year Patients Women(%)
Cut-off applied
(ng/L) Comments
Men Women
hs-cTnT (Roche Diagnostics)
Mueller-
Hennessen et
al. [92]
2016 1282 477 (37%) 15.5 9.0 Sex-specific cut-offs increased MI diagnosis in women (from 17% to 23%)but this did not affect outcomes
15.5 9.0
Reclassification occurred in only 3 patients; no effects on outcomes.
Tested three different sets of sex-specific cut-offsRubini
Gimenez et
al. [91]
2016 2734 876 (32%) 17.0 9.0
12.0 16.0
16.0 9.0 Using sex-specific cut-offs, the prevalence of MI would increase by 3.3%
in women. Sex-specific cut-offs did not improve risk prediction, but the
study identified an increase of risk in women starting at 10-12 ng/L instead
of 14 ng/L.
Eggers et al.
[93] 2016 57556
22027
(38%) 26.0 15.0
34.0 24.0
Mueller et al.
[99] 2018 3588 1643 (46%) 16 9
Sex-specific cut-offs increased myocardial injury diagnosis in 11% of
women compared to a 4% decrease in men
McRae et al.
[94] 2018 7130 3199 (45%)
Several
combinations
according to sex
Implementation of sex-specific cut-offs improved specificity of hs-cTnT in
the diagnostic approach of ACS
Yang et al.
[95] 2016 812 376 (46%)
Several
according to age
and sex
Sex-specific cut-offs were calculated in a healthy Chinese cohort and
further stratified for age
hs-cTnI (Abbott Diagnostics)
Shah et al.
[96] 2018 48282
22562
(47%) 34 16
Sex-specific cut-offs for an hs-cTnI assay, compared to a contemporary
cTnI assay, led to a two-fold myocardial injury reclassification rate in
women; no difference in 1-year outcomes among reclassified patients
treated according to cTnI vs hs-cTnI levels
Shah et al.
[98] 2015 1126 504 (45%) 34 16
Sex-specific cut-offs increase MI diagnosis in women (from 16 to 22%)
while having small effects on men
Mueller et al.
[99] 2018 3588 1643 (46%) 34 16
Sex-specific cut-offs increased myocardial injury diagnosis in 6% of
women compared to a 3% decrease in men
Cullen et al.
[97] 2016 2841 1180 (41%) 34 16
Small amount of women and men reclassified using sex-specific
thresholds, thus improving identification of women at long-term (1 year)
risk for MACE
Eggers et al.
[100] 2014 2750 1073 (39%) 24.8 16.6
Sex-specific cut-offs were derived from a reference population recruited
for the purposes of the study. Sex-specific cut-offs did not show
improvement in the identification of more at-risk patients; however
higher concentrations of troponins show stronger predictive value in
women than men
Bohula May
et al. [101] 2014 4695 1460 (31%) 34 16
Population presenting with typical ischemic symptoms. Using sex-specific
thresholds, only 6 patients were reclassified; no improvement in
prognostic performance.
identification of women at high risk for cardiovascular events
within 1 year. Even so, the authors conclude that the net effect
across the whole ED population with chest pain symptoms
would be minimal and there may be an increased risk of
nonidentification of males at high risk for cardiovascular
events. The limitation of the study, however, was the use of
an overall cut-off to adjudicate endpoints. Overcoming this
limitation would require additional testing in a prospective
trial reporting outcomes following the clinical use of sex-
specific thresholds [97].
Interesting data come from a prospective cohort of 1126
patients with suspected ACS. Classification according to
sex-specific threshold levels for hs-cTnI (34 ng/L in men,
16 ng/L in women versus 26 ng/L as standard reference
value) led to an increase in the number of MI diagnosed
in women (from 16% to 22%) whereas the effect on men
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was less relevant. Furthermore, female patients with levels
of hs-cTnI of 17-26 ng/L presented sixfold rates of death or
recurrentMI at 1 yearwhen compared towomenwith hs-cTnI
≤16 ng/L (23% versus 4%). Similar rates of 1-year outcomes
were observed when comparing women in the 17-26 ng/L
groupwithwomenwith hs-cTnI above the standard reference
value, suggesting that a sex-specific approach improved
the identification of high-risk females in this cohort [98].
While there is further evidence in support of the higher
reclassification rate observed in women when using this
approach [99], a subanalysis of the GUSTO-IV trial failed
to identify an improved risk prediction. Notably, in this
study females accounted for less than 40% of the main
cohort [100]. Likewise, in a study which pooled cohorts
from two randomized controlled trials, small reclassification
rates occurred when using sex-specific cut-offs, thus leading
to no-impact on the prognostic performance of hs-cTnI.
However, the small ratio of females enrolled (31%) and the
population selection criteria (patients presenting with typical
ischemic symptoms) represent important biases to keep into
account when translating these findings to the real world
[101].
6. Conclusions
The influence of patients’ characteristics on biomarkers and
their application to clinical decisions are gaining increasing
importance and consideration in modern medicine. Sex,
among others, represents one of the most important factors
to consider when dealing with markers such as hs-cTn,
whose concentrations can overturn clinical approaches and
workups.
Our review highlights some key aspects. Firstly, algo-
rithms proposed for the work-up of ACS in the ED do not
consider personal characteristics, thus potentially leading
to underdiagnosis and inequality of care. Concerns were
raised regarding the possible impact of sex on this issue,
yet no definitive evidence is available. Secondly, current
evidence clearly shows a significant difference in hs-cTn con-
centrations and reference limits between men and women.
Among healthy people 99th percentile values were found
to be consistently lower in females, even if point values
broadly fluctuate across studies and seem to be closely related
to their reference population. Thirdly, data on the real-
world performance of these sex-specific cut-offs is far more
unclear. While some evidence points to potential benefits
in the classification of high-risk women, several studies
failed to demonstrate an advantage in terms of prognosis
and clinical management [91–93, 102], thus not supporting
their implementation in clinical practice. Some remarks,
however, are mandatory: most of these studies investigated
a single set of sex-related cut-offs, making it difficult to
establish which set (if any) has the better performance in
terms of risk-prediction and prognosis. Moreover, rates of
reclassification (i.e.: patients with a diagnosis upgraded from
UA to NSTEMI) are generally low, partly due to the narrow
gap between the standard cut-off and the threshold applied
to women, thus leading to a scarce impact on the overall
prognosis. This is also confirmed by a recent meta-analysis,
which reported the mean between-sex differences for hs-cTn
in several large populations, as well as showing that the gap
between standard and sex-specific thresholds is narrower for
hs-cTnT, for which the mean difference of sex-specific cut-
offs is close to the limit of detection [103]. In our opinion,
according to the data observed and the slight differences
observed between sexes in terms of hs-cTn upper reference
limits [103], definitive conclusions could only be drawnon the
basis of larger studies involving a higher number of patients
and a more representative proportion of females, who now
account for roughly 35-40% in most studies. Furthermore,
in the context of MI, it is conceivable that most patients will
present high levels of hs-cTn. The application of sex-tailored
cut-offs then, despite the slight reclassification rate, could still
improve the management of a sizeable cluster of patients.
Fourthly, mechanisms underlying this discrepancy have not
yet been fully explained: although some hypotheses have
been reported and several factors outlined, a more thorough
comprehension is required to understand if sex-related cut-
offs could really impact the management of ACS in the ED,
and why. For example, women exhibit higher rates of type-2
MI [104, 105] and microvascular CAD [106], and the extent
to which these differences could impact hs-cTn diagnostic
performance (e.g.: affecting its release kinetics or its peak
values) is still a matter of concern. Further investigations
are required to explore and shed some light on these open
issues.
In conclusion, current literature strongly identifies the
existence of sex-driven differences in hs-cTn levels in refer-
ence populations. The adoption of sex-specific cut-offs is still
debated and knowledge on the potential positive effect than
this could have on the prognosis of ACS in women is partial.
Caution ismandatory due to lacking data on pathophysiology
and further studies are required to clarify whether and why
the adoption of sex-oriented cut-offs could lead to better
management of ACS in women.
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